AstraZeneca: Tagrisso effective as adjuvant treatment
(CercleFinance.com) - At the weekend AstraZeneca announced that it had achieved "unprecedented" survival results in the treatment of early-stage lung cancer with its Tagrisso tablet.
The biopharmaceutical group reported that 88% of patients with EGFR-mutated non-small cell lung cancer enrolled in its "Adaura" phase III clinical trial were still alive after five years.
The company says that Tagrisso reduced the risk of death by 51% compared with placebo, both in the primary target population and in the study population as a whole.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The biopharmaceutical group reported that 88% of patients with EGFR-mutated non-small cell lung cancer enrolled in its "Adaura" phase III clinical trial were still alive after five years.
The company says that Tagrisso reduced the risk of death by 51% compared with placebo, both in the primary target population and in the study population as a whole.
Copyright (c) 2023 CercleFinance.com. All rights reserved.